<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604355</url>
  </required_header>
  <id_info>
    <org_study_id>BP29948</org_study_id>
    <nct_id>NCT02604355</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients</brief_title>
  <official_title>A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose, Adaptive Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Subjects and Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple-center, randomized, double-blind, placebo-controlled, single-ascending&#xD;
      dose and multiple-ascending dose, adaptive parallel study to investigate the safety,&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of RO7020322 following oral&#xD;
      administration in healthy participants and chronic hepatitis B patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Molecule Development was Terminated&#xD;
  </why_stopped>
  <start_date type="Actual">November 28, 2015</start_date>
  <completion_date type="Actual">May 9, 2016</completion_date>
  <primary_completion_date type="Actual">May 9, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of adverse events</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory abnormalities</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital signs abnormalities</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to Cmax (Tmax) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentrations (Ctrough) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve between time zero (pre-dose) and the time of the last quantifiable concentration (AUClast) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve between time zero (pre-dose) extrapolated to infinity (AUC0-Inf) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume (V/F) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (t1/2) of RO7020322</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-t,ss) of RO7020322 at steady state</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-t) of RO7020322 on Day 1</measure>
    <time_frame>Up to 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of hepatitis B surface antigen (HBsAg)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Healthy Participants (Multiple-Ascending Dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants (Single-Ascending Dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants (Study of Food Effect)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Chronic Hepatitis B (Proof of mechanism)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Oral dosing with placebo capsules to match RO7020322.</description>
    <arm_group_label>Healthy Participants (Multiple-Ascending Dosing)</arm_group_label>
    <arm_group_label>Healthy Participants (Single-Ascending Dosing)</arm_group_label>
    <arm_group_label>Healthy Participants (Study of Food Effect)</arm_group_label>
    <arm_group_label>Participants with Chronic Hepatitis B (Proof of mechanism)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7020322</intervention_name>
    <description>Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.</description>
    <arm_group_label>Healthy Participants (Multiple-Ascending Dosing)</arm_group_label>
    <arm_group_label>Healthy Participants (Single-Ascending Dosing)</arm_group_label>
    <arm_group_label>Healthy Participants (Study of Food Effect)</arm_group_label>
    <arm_group_label>Participants with Chronic Hepatitis B (Proof of mechanism)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Participants' Inclusion Criteria:&#xD;
&#xD;
          -  A Body Mass Index (BMI) between 18 to 30 kg/m^2, inclusive, and a body weight of at&#xD;
             least 50 kg&#xD;
&#xD;
          -  Males must agree to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures, and agree to refrain from donating sperm during the study&#xD;
&#xD;
          -  Women should be of non-childbearing potential&#xD;
&#xD;
          -  Able to comply with study restrictions&#xD;
&#xD;
          -  Non-smoker (nor tobacco-containing products) for at least 90 days prior to dosing on&#xD;
             Day 1 and agreeing not to smoke during the study&#xD;
&#xD;
        Chronic Hepatitis B-Infected Participants' Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B infection&#xD;
&#xD;
          -  A BMI between 18 to 32 kg/m^2, inclusive&#xD;
&#xD;
          -  Positive test for HBsAg for more than 6 months prior to randomization&#xD;
&#xD;
          -  On entecavir or tenofovir treatment for at least 6 months prior to randomization and&#xD;
             remaining on stable treatment during the study&#xD;
&#xD;
          -  Liver biopsy, fibroscanÂ® or equivalent test obtained within the past 6 months&#xD;
             demonstrating liver disease consistent with chronic hepatitis B (HBV) infection&#xD;
             without evidence of bridging fibrosis or cirrhosis&#xD;
&#xD;
          -  Males must agree to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures, and agree to refrain from donating sperm during the study&#xD;
&#xD;
          -  Women of childbearing potential must agree to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use non-hormonal contraceptive methods that result in a&#xD;
             failure rate of &lt; 1% per year during the treatment period and for at least until the&#xD;
             end of the follow-up period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy Participants' Exclusion Criteria:&#xD;
&#xD;
          -  Women who are lactating&#xD;
&#xD;
          -  Any suspicion or history of alcohol and/or other substance abuse or dependence in the&#xD;
             past 6 months&#xD;
&#xD;
          -  Positive urine drug and alcohol screen (barbiturates, benzodiazepines, methadone,&#xD;
             amphetamines, methamphetamines, opiates, cocaine, cannabinoids, and alcohol), or&#xD;
             positive cotinine test at Day -1&#xD;
&#xD;
          -  Positive result on HBV, hepatitis C (HCV), or human immunodeficiency virus (HIV) 1 and&#xD;
             2&#xD;
&#xD;
          -  A personal history of unexplained blackouts or faints, or known risk factors for&#xD;
             Torsade de Pointes&#xD;
&#xD;
          -  Clinically significant abnormalities (as judged by the Investigator) in the physical&#xD;
             examination and in the laboratory test results (including hepatic and renal panels,&#xD;
             complete blood count, chemistry panel and urinalysis) at screening and on Day -1&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 90 days prior to&#xD;
             screening or 5 times the half-life of the investigational drug (whichever is longer)&#xD;
&#xD;
          -  Donation of blood over 500 mL within three months prior to screening&#xD;
&#xD;
          -  Concomitant disease or condition (including allergic reactions against any drug, or&#xD;
             multiple allergies) that could interfere with, or treatment of which might interfere&#xD;
             with, the conduct of the study, or that would, in the opinion of the Investigator,&#xD;
             pose an unacceptable risk to the healthy participant in this study&#xD;
&#xD;
        Chronic Hepatitis B-Infected Participants' Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant (positive pregnancy test) or lactating&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices&#xD;
&#xD;
          -  Decompensated liver disease&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HBV infection&#xD;
&#xD;
          -  Documented history or other evidence of metabolic liver disease within one year of&#xD;
             randomization&#xD;
&#xD;
          -  Positive test for hepatitis A (IgM anti-HAV), hepatitis C, or HIV&#xD;
&#xD;
          -  Documented history of infection with hepatitis D virus&#xD;
&#xD;
          -  Expected to need systemic antiviral therapy other than that provided by the study at&#xD;
             any time during their participation in the study, with the exception of oral therapy&#xD;
             for herpes simplex virus (HSV) I or HSV II&#xD;
&#xD;
          -  History of immunologically-mediated disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauranga Hospital</name>
      <address>
        <city>Tauranga</city>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

